Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1056/NEJMc2403590 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Cefepime-taniborbactam: Ushering in the era of metallo-β-lactamase inhibition.
Pharmacotherapy
July 2025
Anti-Infective Research Laboratory, Department of Pharmacy Practice, Eugene Applebaum College of Pharmacy and Health Sciences, Wayne State University, Detroit, Michigan, USA.
Carbapenem-resistant Enterobacterales (CRE) and Pseudomonas aeruginosa (CR-PA) continue to pose a significant threat to human health. Furthermore, the prevalence of metallo-β-lactamase (MBL)-producing CRE and CR-PA is increasing, which are capable of hydrolyzing nearly all β-lactam antibiotics. Cefepime-taniborbactam (FTB) is a novel bicyclic boronate β-lactam-β-lactamase inhibitor combination with direct inhibitory activity against MBLs (Ambler Class B), in addition to Ambler Class A, C, and D serine-β-lactamases.
View Article and Find Full Text PDFNephrology: What You May Have Missed in 2024.
Ann Intern Med
May 2025
Division of Nephrology, The MetroHealth System, Case Western Reserve University, Cleveland, Ohio (A.R.S.).
This article highlights some important nephrology studies published in 2024 that may be relevant for nonnephrologist physicians. Four studies examined progression of chronic kidney disease (CKD), cardiovascular events, and nephrolithiasis with respect to use of semaglutide or sodium-glucose cotransporter-2 inhibitors. Three studies examined treatments to improve specific aspects of CKD management, including mineralocorticoid receptor agonists to address heart failure, avenciguat to address albuminuria, and oral phosphate binders to address fracture risk.
View Article and Find Full Text PDFCefepime-Taniborbactam: A Novel Cephalosporin/β-Lactamase Inhibitor Combination.
Drugs
October 2024
Department of Medical Microbiology and Infectious Diseases, Max Rady College of Medicine, Rady Faculty of Health Sciences, University of Manitoba, 502 Basic Medical Sciences Building, 745 Bannatyne Avenue, Winnipeg, MB, R3E 0J9, Canada.
Taniborbactam (formerly known as VNRX-5133) is a novel bicyclic boronate β-lactamase inhibitor of serine β-lactamases (SBLs) [Ambler classes A, C, and D] and metallo-β-lactamases (MBLs) [Ambler class B], including NDM and VIM, but not IMP. Cefepime-taniborbactam is active in vitro against most isolates of carbapenem-resistant Enterobacterales (CRE) and carbapenem-resistant Pseudomonas aeruginosa (CRPA), including both carbapenemase-producing and carbapenemase-non-producing CRE and CRPA, as well as against multidrug-resistant (MDR), ceftazidime-avibactam-resistant, meropenem-vaborbactam-resistant, and ceftolozane-tazobactam-resistant Enterobacterales and P. aeruginosa.
View Article and Find Full Text PDFNovel Antibiotics for Urinary Tract Infection (UTI): The EAGLE 2 and EAGLE-3 Trials for Uncomplicated UTI, and the CERTAIN-1 Trial for Complicated UTI.
Eur Urol Focus
September 2024
Clinic of Urology, Pediatric Urology and Andrology, Justus Liebig University Giessen, Giessen, Germany. Electronic address:
Two novel antibiotics have been evaluated for the treatment of urinary tract infection (UTI). Gepotidacin was an efficacious first-in-class oral antibiotic in uncomplicated UTI in comparison to nitrofurantoin. Cefepime/taniborbactam was superior to meropenem in complicated UTI and acute pyelonephritis.
View Article and Find Full Text PDFIn complicated UTIs, cefepime-taniborbactam increased treatment success vs. meropenem at 19 to 23 d.
Ann Intern Med
June 2024
University of Texas MD Anderson Cancer Center, Houston, Texas, USA (B.G.).
Wagenlehner FM, Gasink LB, McGovern PC, et al; CERTAIN-1 Study Team. N Engl J Med. 2024;390:611-622.
View Article and Find Full Text PDF